DOCSLIB.ORG

Effect of Ulinastatin Combined Rivaroxaban on Deep Vein Thrombosis in Major Orthopedic Surgery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Ulinastatin Combined Rivaroxaban on Deep Vein Thrombosis in Major Orthopedic Surgery Asian Pacific Journal of Tropical Medicine (2014)918-921 918 Contents lists available at ScienceDirect IF: 0.926 Asian Pacific Journal of Tropical Medicine journal homepage:www.elsevier.com/locate/apjtm Document heading doi: 10.1016/S1995-7645(14)60162-0 Effect of ulinastatin combined rivaroxaban on deep vein thrombosis in major orthopedic surgery Xi Yu1,2, Yi Tian2, Ka Wang2,Ying-Lin Wang2, Guo-Yi Lv1, Guo-Gang Tian2* 1Department of Anesthesiology, 2nd hospital of Tianjin Medical University, Tianjin 300211, China 2Department of Anesthesiology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, China ARTICLE INFO ABSTRACT Article history: Objective: ( ) To explore the effect of ulinastatin UTI continuous infusion combined RivaroxabanMethods: Received 24 August 2014 on the deep vein thrombosis in patients undergoing major orthopedic surgery. Received in revised form 10 September 2014 Forty-five patients undergoing major orthopedic surgery were randomly divided into three Accepted 15 October 2014 (U ) (U ) Available online 20 November 2014 groups:ulinastatin continuous infusion c group, ulinastatin single injection s group and control (C) group. All patients received patient-controlled intravenous analgesia (PCIA) after R 10 12 U (5 000 U ) Keywords: operation, and took ivaroxaban mg orally hours after operation. linastatin /kg was given intravenously to both Uc and Us groups preoperatively. Group C was given isometric Ulinastatin normal saline, group Uc was pumped UTI continuous intravenously at the end of surgery (10 000 Rivaroxaban U/kg) to 48 hours through PCIA pump. The values of hematocrit (HCT), thrombomodulin (TM), DVT Interleukin (IL-6), thrombin-antithrombin complex (TAT), D-Dimer (D-D) were normally tested Orthopedic surgery ( ) ( ) ( ) ( ) ( ) before surgeryResults: T1 , at the end of the surgery T2 , 12 hours T3 , 24 hours T4 and 48 hours T5 C T1 TM IL 6 TAT after surgery. ompared with P , there was an upward tendency in , - , , and D D C ( 0 05) T - after operation in group group < . Phe values of them were significantly increased 24 U ( 0 05) I U from nearly -hour after surgery in s Pgroup Conclusions:< . n group c, there were no significant changes in these indices after operation ( >0.05). During the perioperative period, ulinastatin continuous infusion combined Rivaroxaban can correct blood hypercoagulability through different approaches in patients undergoing major orthopedic surgery. anticoagulation and unpredictable blood drug concentration 1. Introduction is limiting its application. Ulinastatin, an acid glycoprotein which contained in the fresh urine of healthy humans, is Deep vein thrombosis (DVT) is the most common and well known to inhibit the activity of inflammation. The serious complication after the major orthopedic surgery, recent researches show that UTI could inhibit coagulation which includes total hip replacement (THR), total knee and fibrolysis by inhibiting the leukocyte activity. Therefore, replacement (TKR) and hip fractures surgery (HFS). Despite the combination therapy of revaroxban and UTI perhaps active anticoagulant therapy is given after the surgery, the advance the development of anticoagulant regiment. fatality rate of the DVT can reached 3.8%, and the fatality rate of the pulmonary thromboembolism (PTE) can reached 2. Materials and methods 38.9%[1]. Although compared to traditional anticoagulants, the new 2.1. Participants and inclusion criteria oral anticoagulant- rivaroxaban has advantages of safe dose rang and noninvasive administration, but the single mode of After local ethics committee approval and written informed consent, 45 ASA 栺 or 栿 patients, aged 40-90 yr, scheduled *Corresponding author: Guo-Gang Tian, Department of Anesthesiology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, for elective total hip replacement or hip fracture surgery, China. were enrolled in this study. Patients with such coexisting Tel: +86-18222471718 E-mail: [email protected] diseases or conditions as preoperative bleeding, clotting Foundation project: It is supported in part by Scientific Research Fund of Hainan disorders, an abnormal coagulation test, thrombocytopenia, Provincial Health Department (No.2010-83). Xi Yu et al./Asian Pacific Journal of Tropical Medicine (2014)918-921 919 and severe renal, hepatic or heart disease were excluded. 3. Results Aspirin and other antiplatelet agents were discontinued 7 days before the scheduled procedure. 3.1. General observation Patients were randomly divided into three groups: ulinastatin continuous infusion (Uc) group, ulinastatin single injection (Us) group and control (C) group. The general data compared with treatment group and (T 1) 2.2. Treatments control group as followsP able , and there was no significantly differences ( >0.05) in sex, age, type of surgery, etc. No significant change of the HCT was found between After enter the operating room and before the anesthesia three groups in each time point, which excluded the effect of induction, Uc and Us group were premedicated with UTI blood dilution on the experimental results (Table 2). [2] 5 000 U/kg , which was dissolved in normal saline 100 mL, Table 1 Group C was given isometric normal saline. Spinal anesthesia Comparison of background variables. was performed at the L2-L3 interspace as the patient in lateral position. All patients received a patient-controlled Issues Uc Us C intravenous analgesia (PCIA) for 48 h postoperatively. The Sex (M/F) 8/7 9/6 8/7 PCIA setting was as follows: background infusion fentanyl Age 68.27依13.26 69.80依11.97 66.73依13.89 BMI 22.31依1.55 21.92依1.47 21.51依1.60 20 毺g/kg and ondansetron 8 mg, which was dissolved in NS to 100 mL, at a rate of 2 mL/h, bolus dose 0.5 mL, lockout Type (THR/HFS) 11/4 12/3 11/4 inerval 15 min. The patients in Uc group were received UTI OR time(min) 79.00依23.69 80.33依28.31 80.33依26.35 continuous infusion of 10 000 U/kg to 48 hours with the help Blood loss(mL) 124.00依61.04 150.67依78.96 142.33依72.97 of infusion pump. If visual analog scale (VAS) >3 in spite of Infusion(mL) 973.33依187.91 923.33依273.77 1 093.33依405.26 treatment, a second dose of analgesic (fentanyl 0.05 mg) was Table 2 n given. Changes of hematocrit in three groups ( =15, %, mean依sd). All the operations were conducted by the same surgery Indexes Uc Us C and anesthesia team. All the patients took rivaroxaban HCT T1 38.31依3.93 36.34依4.75 38.36依3.65 10 mg orally 12 hours after the operation. Tests would be T2 33.75依4.38 31.63依4.32 33.37依3.30 discontinued if the tendency of bleeding occurred. T3 34.3依5.66 33.5依5.77 33.30依3.17 2.3. Clinical evaluation and laboratory examination T4 32.42依5.93 31.57依3.36 32.25依3.27 T5 30.91依5.50 29.76依3.24 30.85依2.52 The operation time, blood loss and the infusion were 3.2. TM scores recorded. Blood sample were obtained for analysis of Hematocrit A T 3 TM (HCT), thrombomodulin (TM), Interleukin-6 (IL-6), thrombin- s shown in able , score was graduallyP increased C 48 ( 0 05) H antithrombin complex (TAT), D-Dimer (D-D) levels at 5 in group till hours after theP surgery < . owever, U ( 0 05) T TM intervals: before surgery (T1) , at the end of the surgery (T2) it was declined in c group < . he scoreP was , 12 hours (T3) , 24 hours (T4), 48 hours (T5) after the surgery. significantly increase 24 hours after single injection ( <0.05). HCT were detected with hematology analyzer (SysmexXE- 3.3. IL-6 scores 2100). Serum IL-6, TAT, D-D, TM concentrations were assayed by ELISA (R&D company, America). As shown in Table 4, after the surgery, both ulinastatin 2.4. Statistical analysis single injection group and ulinastatin continuous Pinfusion group showed no conspicuous change in IL-6 ( >0.05). 2 H IL 6 Statistical analysis was performed with the 氈 test of owever, theP level of - in control group was significantly the sex and type of surgery. One-way factorial analysis of increased ( <0.05). But 24 hours after single injection, the (ANOVA) IL-6 score in Uc group were significant increase as in C varianceP was used in analysis of other demographic P ( 0 05) N U data. value <0.05 was considered as statistically significant group < . o outstanding changeP was observed in c difference. group till 48 hours after the surgery ( >0.05). Table 3 n Changes of TM in three groups ( =15,毺g/L, mean依sd). Groups T1 T2 ●▲ T3 ●▲ T4 ●▲ T5 ●▲ Uc 47.36依15.07 40.42依9.37 ● 40.60依8.80● 34.82依6.19 ▲ 43.98依13.14▲ Us 41.93依11.42 42.35依8.45▲ 44.18依8.98▲ 50.50依14.33▲ 57.00依9.52▲ C 44.33依8.00▲ 51.62依7.66 53.86依7.47 54.72依8.47 57.10依8.31 ● P P Compared with group C, <0.05; Compared with T1, <0.05. Xi Yu et al./Asian Pacific Journal of Tropical Medicine (2014)918-921 920 3.4. TAT scores diagnosed from imageology, it is hard to be cured. So the early prophylaxis and discovery of thrombophilia is the key From Table 5, it showed that TAT exhibited roughly to prevent DVT. 48 C P increasingP tendency after the surgery for hours in revious studies showed that low molecular heparin ( 0 05) H U U group < . , owever,P c group and s group showed no injected subcutaneously could be used to prevent and cure significant changes ( >0.05). DVT effectively. Meanwhile, the potent anticoagulant effect 3.5. D-D scores could cause bleeding tendency, and it is one typical side effect. Moreover, the way of invasive administration reduces the clinical compliance of patients. Recently, it has been As shown in Table 6, 12 hours after the surgery, no reported that one kind of new oral anticoagulant rivaroxaban remarkable changes was found in D-D serous concentration is replacing its anticoagulation status gradually as a result U R of both linastatin single injectionP group and ulinastatin of simple and noninvasive application.
Load more

Recommended publications
  • Download This PDF File
    Med J Chin PLA, Vol. 42, No. 12, December 1, 2017 ǂ1029 䃲eڝeᠳࢃ̺ ӵϔߙᡇ੢ϊҍᣴ໓͌ܠ੠ᣴ̹ࢴҝᣱ ͙఩ࡧጴࡻцᕑ䃶ܲц ᕑ᩽ࡧ႒̿͆ༀ঄цۇ͙఩Ϧℽ㼏ᩪ 䛹⫳ࡧ႒̿͆ༀ঄цۇ͙఩Ϧℽ㼏ᩪ ͙఩ࡧጴࡻцᕑ䃶ܲцᕑ䃶โ⻽̿͆ༀ঄ц 喞ᕑ᩽ٷ䩚䃹]Ȟ݇ѐ喞๝㵬ᕓнڟ] [͙పܲㆧण]ȞR605.97ȞȞȞȞ[᪳⡚ᴳᔃⴭ]ȞAȞȞȞȞ[᪳「㑂ण]Ȟ0577-7402(2017)12-1029-10 [DOI]Ȟ10.11855/j.issn.0577-7402.2017.12.02 Chinese emergency medicine expert consensus on diagnosis and treatment of traumatic hemorrhagic shock Emergency Medicine Branch of Chinese Medical Doctor Association People’s Liberation Army Professional Committee of Emergency Medicine People’s Liberation Army Professional Committee of Critical Care Medicine Professional Committee of Emergency Surgery, Emergency Medicine Branch of Chinese Medical Doctor Association 1ȞẮȞȞ䔜 ㏒10%⤯ڔѐ᭛ᠳᱦᷜ߇҈⩔κϦѿऺᝬ䕌᜼⮰ᱦѿ㏿ᲰႸ᪠ᕓ⮰ⵠ౻সߋ㘩䯈ⶹȠᢚWHO㐋䃍喏݇ 40ᆭБ̷Ϧ㓐⮰仂㺭₧ఌ[1]Ƞ⤯ڔ⮰₧ύস16%⮰㜠₷⫱ҷఌ݇ѐᝬ㜠喏सᬢ݇ѐ΋᭛ ᄽȟ㏰㏳╸∔̹䋟ȟ㏲㘊Џ䅎㈶Νসۻ᭛ᠳ݇ѐ䕌᜼ᱦѿ๓䛻๝㵬ᝬ㜠ᰵᩴᓖ⣛㵬䛻ٷѐ๝㵬ᕓн݇ ፤፤ऴᎢѺ㵬ࢷ(჆͵ͦᩢ㑕ࢷ┯90mmHg喏㘵ࢷ┯20mmHg喏ᝂ࣋ᰵ倄㵬ٷஔჄߋ㘩ःᢋ⮰⫱⤲⩋⤲䓳⼷Ƞн ࢷ㔱ᩢ㑕ࢷ㜖ദ㏫̷䭹Ĺ40mmHg)Ƞ30%~40%⮰݇ѐᗏ㔱₧ύ᭛ఌ๝㵬䓳ๆᝬ㜠喏ₐㆧᗏ㔱͙喏ᰵ̬䘔ܲ ఌͦ䩅䄛⮰᩽⇧᫥ᵴࣶ̹ᖜᑿ⮰⇧⫃ᣖ᫩㔸₧ύ喏ࢌ10%~20%Ƞᕑᕓ๝㵬᭛݇ѐ仂㺭⮰छ䶰䭞ᕓ₧ఌ[2-3]Ƞ ᄽๆஔჄߋ㘩䯈ⶹ㐨ऴᒭۻ䛹㺭喏छᰵᩴڟᄥκ͑䛹݇ѐᗏ㔱㜟ٷ㵬喏㏌₏๝㵬ᕓнܦࣶᬢȟᔗ䕋ᣓݢ (multiple organ dysfunction syndrome喏MODS)⮰ࣽ⩋喏䭹Ѻ₧ύ⢳Ƞ ⮰ᕑ䃶᩽ٷ䃲ᬔ౔㻰㠯স᣼倄݇ѐ๝㵬ᕓнڝᠳࢃȠ᱘ڟᕑ᩽⇧⮰Ⱔ㉓ٷⰚݹ᜽఩ᅆᬌ݇ѐ๝㵬ᕓн ⇧喏ͦᕑ䃶ࡧጴ᣼Ӈ䃶⫃ӉᢚȠ ⤲⩋⤲⫱⮰ٷ2Ȟ݇ѐ๝㵬ᕓн ᭛㵬ქ䛻̺㵬ネქ⼛⮰̹ࡥ䙹喏䕌᜼โঔ㏰㏳╸∔̹䋟喏Ϻ㔸ᑁٴ⮰⫱⤲⩋⤲ऄࡂ仂ٷѐ๝㵬ᕓн݇ 㘻ஔჄ⮰㐓ࣽᕓᢋჟȠڱ㵬䯈ⶹБࣶ܉䊣ᓚᓖ⣛ऄࡂȟ⅓Џ䅎ߔ߇႒ᐮ፤ȟ►⫳ࣹᏀȟ ᭛䛹㺭㘻ڢᰬᵥ᱘⮰⫱⤲⩋⤲ᩥऄ᭛๝㵬ᝬ㜠⮰ᓚᓖ⣛ߋ㘩䯈ⶹ喏ᅐٷ2.1Ȟᓚᓖ⣛ऄࡂȞ݇ѐ๝㵬ᕓн ၼὍᐻ(damage associatedܲڟϓ⩋ᢋѐⰤٷஔᓚᓖ⣛ᩥऄȠᄨ㜠ᓚᓖ⣛ߋ㘩䯈ⶹ⮰ͧ㺭ᱦݢ࠱᠘喝Ŗн Ꮐむࣶ๝ᣓᕓ►⫳ࣹᏀ喏ᑁ䊣㵬⫗ٹ㯷⮩স倄䓭⼧⢳᫻㯷⮩1㼒ࣽٷmolecular patterns喏DAMP)[4-5]喏ຮ☙н 㵬㈧܉⯚ᢋѐᑁ䊣ڱᄽ喏ᰬ㏴ᄨ㜠㏰㏳╸∔̹䋟ȟ㏲㘊㑦⅓喞ŗۻ⯚ᢋѐȟℇ㏲㵬ネ⍃␻ȟᓖ⣛ქ䛻ڱネ 㐋⓬≧ȟᓚ㵬ᴿᒎ᜼喏䭧ඊℇ㏲㵬ネࣶ㵬ネ㜾㑕ߋ㘩䯈ⶹ喏ߌ䛹㏰㏳㑦㵬㑦⅓喞Ř݇ѐᝬ㜠⮰ᠭ㐙ȟᑦ◴ ᓚᓖ⣛䯈ⶹȠޓߋ㘩喏ᄨ㜠ࣹᄰᕓ㵬ネ㜾㑕ߋ㘩㈶Ν喏ߌ⇸ܲڱ⮰ݦ⓬ᒝ৹⺊㏻ ⅓̺(ᗏ㔱ႄ౔⅓Џ䅎ߔ߇႒ᐮ፤喏࢟⅓ӇᏀ(DO2ٷ2.2Ȟ⅓Џߔ߇႒ᐮ፤ࣶ㏲㘊Џ䅎ᩥऄȞ݇ѐ๝㵬ᕓн
    [Show full text]
  • Urinary Trypsin Inhibitor: Miraculous Medicine in Many Surgical Situations?
    Korean J Anesthesiol 2010 Apr; 58(4): 325-327 Editorial DOI: 10.4097/kjae.2010.58.4.325 Urinary trypsin inhibitor: miraculous medicine in many surgical situations? Jong In Han Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, Seoul, Korea Recently, we encounter several articles regarding urinary Trypsin inhibitors act to suppress the proteolytic action trypsin inhibitor (UTI) published nationally [1,2]. When we take of trypsin on a variety of tissues and exert a localized anti- a glance at these articles, it feels like UTI acts as a miraculous inflammatory effect [8]. Therefore UTI is indicated for acute medicine on patients under general anesthesia because of inflammatory disorders, including acute pancreatitis, systemic its protection effect against surgical stress. Yet, even after the inflammatory reaction syndrome, circulatory insufficiency, first report on antitryptic action of urine by Bauer and Reich Stevens-Johnson syndrome, Toxic epidermal necrolysis (TEN), III in 1909 [3]; the start of use of the term UTI by Astrup and disseminated intravascular coagulation (DIC) and multiple Sterndorff in 1955 [4]; and numerous animal experiments and organ failure [9]. Previous studies of UTI have focused mainly clinical research done about UTI (803 articles about UTI and on modulating inflammatory reaction. UTI attenuates the 982 articles about ulinastatin in SCOPUS), UTI is not yet to elevation of neutrophil elastase release, thereby blunting the be used commonly. Therefore, it is important to understand rise of pro-inflammatory cytokine level; however, the actual the reason behind this situation. According to the webpage of mechanism in vivo is not clear [10].
    [Show full text]
  • A Study on Ulinastatin in Preventing Post ERCP Pancreatitis
    International Journal of Advances in Medicine Vedamanickam R et al. Int J Adv Med. 2017 Dec;4(6):1528-1531 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175083 Original Research Article A study on ulinastatin in preventing post ERCP pancreatitis R. Vedamanickam1, Vinoth Kumar2*, Hariprasad2 1Department of Medicine, 2Department of Gasto and Hepatology , SREE Balaji Medical College and Hospital, Chrompet, Chennai, Tamil Nadu, India Received: 19 September 2017 Accepted: 25 October 2017 *Correspondence: Dr. Vinothkumar, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Pancreatitis remains the major complication of endoscopic retrograde cholangiopancreatography (ERCP), and hyperenzymemia after ERCP is common. Ulinastatin, a protease inhibitor, has proved effective in the treatment of acute pancreatitis. The aim of this study was to assess the efficacy of ulinastatin, compare to placebo study to assess the incidence of complication due to ERCPP procedure. Methods: In this study a randomized placebo controlled trial, patients undergoing the first ERCP was randomizing to receive ulinastatin one lakh units (or) placebo by intravenous infusion one hour before ERCP for ten minutes duration. Clinical evaluation, serum amylase, ware analysed before the procedure 4 hours and 24 hours after the procedure. Results: Total of 46 patients were enrolled (23 in ulinastatin and 23 in placebo group).
    [Show full text]
  • Early Local Drug Therapy for Pancreatic Contusion and Laceration
    Pancreatology 19 (2019) 285e289 Contents lists available at ScienceDirect Pancreatology journal homepage: www.elsevier.com/locate/pan Early local drug therapy for pancreatic contusion and laceration Cong Feng a, 1, Hao Yang e, 1, Sai Huang c, 1, Xuan Zhou a, 1, Lili Wang a, Xiang Cui d, *** ** * Li Chen a, , 2, Faqin Lv b, , 2, Tanshi Li a, , 2 a Department of Emergency, First Medical Center, General Hospital of the PLA, Beijing, 100853, China b Department of Ultrasound, Hainan Hospital of the PLA General Hospital, Sanya, 572000, China c Department of Hematology, First Medical Center, General Hospital of the PLA, Beijing, 100853, China d Department of Orthopedics, First Medical Center, General Hospital of the PLA, Beijing, 100853, China e Department of Radiation Oncology, Inner Mongolia Cancer Hospital & Affiliated People's Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, 010020, China article info abstract Article history: Objectives: To study the therapeutic effect of early local drug therapy on pancreatic contusion and Received 18 September 2018 laceration. Received in revised form Methods: Twenty pigs were divided into 4 groups: model(PL), 1 ml of saline; medical protein glue (EC), 12 December 2018 1 ml of medical protein glue; ulinastatin (UL), 50000U of ulinastatin; combined treatment (UE), 1 ml of Accepted 16 January 2019 medical protein glue and 50000U of ulinastatin. 30 min after model establishment, different groups Available online 17 January 2019 received different local drug treatments. The pancreatic function, peritoneal effusion and pancreatic pathology were observed. Keywords: Pancreatic contusion and laceration Results: The UE group got the best therapeutic effect.
    [Show full text]
  • Antiproteases in Preventing Post-ERCP Acute Pancreatitis
    JOP. J Pancreas (Online) 2007; 8(4 Suppl.):509-517. ROUND TABLE Antiproteases in Preventing Post-ERCP Acute Pancreatitis Takeshi Tsujino, Takao Kawabe, Masao Omata Department of Gastroenterology, Faculty of Medicine, University of Tokyo. Tokyo, Japan Summary there is no other randomized, placebo- controlled trial on ulinastatin under way. Pancreatitis remains the most common and Large scale randomized controlled trials potentially fatal complication following revealed that both the long-term infusion of ERCP. Various pharmacological agents have gabexate and the short-term administration of been used in an attempt to prevent post-ERCP ulinastatin may reduce pancreatic injury, but pancreatitis, but most randomized controlled these studies involve patients at average risk trials have failed to demonstrate their of developing post-ERCP pancreatitis. efficacy. Antiproteases, which have been Additional research is needed to confirm the clinically used to manage acute pancreatitis, preventive efficacy of these antiproteases in would theoretically reduce pancreatic injury patients at a high risk of developing post- after ERCP because activation of proteolytic ERCP pancreatitis. enzymes is considered to play an important role in the pathogenesis of post-ERCP pancreatitis. Gabexate and ulinastatin have Introduction recently been evaluated regarding their efficacy in preventing post-ERCP ERCP is widely performed for the diagnosis pancreatitis. Long-term (12 hours) infusion of and management of various pancreaticobiliary gabexate significantly decreased the incidence diseases. Early complications after ERCP of post-ERCP pancreatitis; however, no include acute pancreatitis, bleeding, prophylactic effect was observed for short- perforation, and infection (cholangitis and term infusion (2.5 and 6.5 hours). These cholecystitis) [1, 2]. Of these ERCP-related results may be due to the short-life of complications, pancreatitis remains the most gabexate (55 seconds).
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Ulinastatin Treatment for Acute Respiratory Distress Syndrome In
    Zhang et al. BMC Pulmonary Medicine (2019) 19:196 https://doi.org/10.1186/s12890-019-0968-6 RESEARCH ARTICLE Open Access Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials Xiangyun Zhang1,2†, Zhaozhong Zhu3†, Weijie Jiao2, Wei Liu1, Fang Liu1* and Xi Zhu4* Abstract Background: Epidemiologic studies have shown inconsistent conclusions about the effect of ulinastain treatment for acute respiratory distress syndrome (ARDS). It is necessary to perform a meta-analysis of ulinastatin’s randomized controlled trials (RCTS) to evaluate its efficacy for treating ARDS. Methods: We searched the published RCTs of ulinastatin treatment for ARDS from nine databases (the latest search on April 30th, 2017). Two authors independently screened citations and extracted data. The meta-analysis was performed using Rev. Man 5.3 software. Results: A total of 33 RCTs involving 2344 patients satisfied the selection criteria and were included in meta- analysis. The meta-analysis showed that, compared to conventional therapy, ulinastatin has a significant benefit for ARDS patients by reducing mortality (RR = 0.51, 95% CI:0.43~0.61) and ventilator associated pneumonia rate (RR = 0.50, 95% CI: 0.36~0.69), and shortening duration of mechanical ventilation (SMD = -1.29, 95% CI: -1.76~-0.83), length of intensive care unit stay (SMD = -1.38, 95% CI: -1.95~-0.80), and hospital stay (SMD = -1.70, 95% CI:-2.63~−0.77). Meanwhile, ulinastatin significantly increased the patients’ oxygenation index (SMD = 2.04, 95% CI: 1.62~2.46) and decreased respiratory rate (SMD = -1.08, 95% CI: -1.29~-0.88) and serum inflammatory factors (tumor necrosis factor-α: SMD = -3.06, 95% CI:-4.34~-1.78; interleukin-1β: SMD = -3.49, 95% CI: -4.64~-2.34; interleukin-6: SMD = -2.39, 95% CI: -3.34~-1.45; interleukin-8: SMD = -2.43, 95% CI: -3.86~-1.00).
    [Show full text]
  • Postoperative Pancreatic Fistula: a Review of Traditional and Emerging Concepts
    Journal name: Clinical and Experimental Gastroenterology Article Designation: REVIEW Year: 2018 Volume: 11 Clinical and Experimental Gastroenterology Dovepress Running head verso: Nahm et al Running head recto: Management of postoperative pancreatic fistula open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CEG.S120217 Open Access Full Text Article REVIEW Postoperative pancreatic fistula: a review of traditional and emerging concepts Christopher B Nahm1–3 Abstract: Postoperative pancreatic fistula (POPF) remains the major cause of morbidity after Saxon J Connor4 pancreatic resection, affecting up to 41% of cases. With the recent development of a consensus Jaswinder S Samra1,2,5 definition of POPF, there has been a large number of reports examining various risk factors, Anubhav Mittal1,2,5 prediction models, and mitigation strategies for this costly complication. Despite these strate- gies, the rates of POPF have not significantly diminished. Here, we review the literature and 1Upper Gastrointestinal Surgical Unit, Royal North Shore Hospital, Sydney, evidence regarding both traditional and emerging concepts in POPF prediction, prevention, and Australia; 2Northern Clinical School, management. In particular, we review the evidence for the association between postoperative Sydney Medical School, The University pancreatitis and POPF, and present a novel proposed mechanism for the development of POPF. of Sydney, Sydney, Australia; 3Bill Walsh Translational Cancer Research Keywords: postoperative pancreatic fistula,
    [Show full text]
  • Supplement II to the Japaneses Pharmacopoeia Fourteenth Edition
    The Ministry of Health, Labour and Welfare Ministerial Notiˆcation No. 461 In accordance with the provisions of Article 41, Paragraph 1 of the Pharmaceutical AŠairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Phar- macopoeia (Ministerial Notiˆcation No. 111, 2001) as follows, and the revised Japanese Pharmacopoeia shall come into eŠect on January 1, 2005, [including dele- tion from O‹cial Monographs fro Part II in The Japanese Pharmacopoeia, Four- teenth Edition of the articles of Absorbent Cotton, Puriˆed Absorbent Cotton, Sterile Absorbent Cotton, Sterile Puriˆed Absorbent Cotton and Absorbent Gauze and Sterile Absorbent Gauze (hereinafter referred to as ``sanitary materials'')]. Provi- so: With respect to the drugs which are included in the Japanese Pharmacopoeia (hereinafter referred to as ``the old Japanese Pharmacopoeia'') [limited to those included in the Japanese Pharmacopoeia whose standards are changed with this notiˆcation published (hereinafter referred to as ``the new Japanese Phar- macopoeia'')] and those which are approved as of January 1, 2005 pursuant to the provisions of Article 14, Paragraph 1 of this Law (including cases where it shall apply mutatis mutandis under Article 23 of this Law; the same hereinafter) [including the drugs designated as those exempted from approval (hereinafter referred to as ``the drugs exempted from approval'') among the drugs etc. designated by the Minister of Health, Labour and Welfare as those exempted from manufacturing or import approval pursuant to the provisions of Article 14, Paragraph 1 of the Pharmaceutical AŠairs Law (Ministerial Notiˆcation No. 104, 1994), the standards established in the old Japanese Pharmacopoeia (limited to the standards for the relevant drugs) shall be recognized, up to June 30, 2006, as the standards established in the new Japanese Pharmacopoeia.
    [Show full text]
  • Effect of Ulinastatin on Myocardial Ischemia Reperfusion Injury Through ERK Signaling Pathway
    European Review for Medical and Pharmacological Sciences 2019; 23: 4458-4464 Effect of ulinastatin on myocardial ischemia reperfusion injury through ERK signaling pathway H. CHE, Y.-F. LV, Y.-G. LIU, Y.-X. HOU, L.-Y. ZHAO Department of Anesthesiology, Beijing Anzhen Hospital of Capital Medical University, Beijing, China Abstract. – OBJECTIVE: To study the ef- Introduction fect of ulinastatin (UTI) on myocardial isch- emia-reperfusion injury (MIRI) through the ex- Acute myocardial infarction ranks first in the tracellular signal-regulated kinase (ERK) signal- cause of death in patients in China. The area and ing pathway. severity of myocardial infarction seriously affect MATERIALS AND METHODS: A total of 24 the prognosis of patients. Although early reperfu- Sprague-Dawley rats were randomly divided in- sion therapy is the most direct and effective means to sham group (n=8), I/R group (n=8), and UTI group (n=8), and the rat model of MIRI was to reduce the area of myocardial infarction, the established. The changes in the content of se- dysfunction and structural damage of ischemic rum biochemical indexes, including superoxide myocardium cannot be repaired in the first time dismutase (SOD) and malondialdehyde (MDA), or even become worse after reperfusion, which is were detected using the kits, and the changes in known as ischemia-reperfusion injury1, seriously the expressions of serum inflammatory factors, hindering the greatest efficacy of reperfusion including interleukin-6 (IL-6) and tumor necro- therapy. Therefore, finding new treatment means sis factor-α (TNF-α), were detected using the to protect ischemic myocardium has become a quantitative Reverse Transcription-Polymerase problem urgently to be solved in the reperfusion Chain Reaction (qRT-PCR) and enzyme-linked therapy of acute myocardial infarction2.
    [Show full text]
  • Erweiterungen Und Änderungen Der ATC- Klassifikation
    GKV-Arzneimittelindex Erweiterungen und Änderungen der ATC- Klassifikation der amtlichen Fassung des ATC-Index mit DDD- Angaben für Deutschland im Jahr 2020 im Vergleich zur amtlichen Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2019 Impressum Die vorliegende Publikation ist ein Beitrag des Wissenschaftlichen Institut der AOK (WldO). GKV-Arzneimittelindex Erweiterungen und Änderungen in der ATC-Klassifikation der amtlichen Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2020 im Vergleich zur amtlichen Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2019 Berlin, Dezember 2019 Wissenschaftliches Institut der AOK (WldO) im AOK-Bundesverband GbR Rosenthaler Str. 31, 10178 Berlin Geschäftsführender Vorstand: Martin Litsch (Vorsitzender) Jens Martin Hoyer (stellv. Vorsitzender) http://www.aok-bv.de/impressum/index.html Aufsichtsbehörde: Senatsverwaltung für Gesundheit, Pflege und Gleichstellung –SenGPG– Oranienstraße 106, 10969 Berlin Satz: Anja Füssel Titelfoto: Kompart Nachdruck, Wiedergabe, Vervielfältigung und Verbreitung (gleich welcher Art), auch von Teilen des Werkes, bedürfen der ausdrücklichen Genehmigung. E-Mail: [email protected] Internet: http://www.wido.de Inhalt 1 Neu aufgenommene ATC-Codes ............................................................................ 4 2 Änderungen der ATC-Bedeutung ........................................................................... 7 3 Verschiebungen der ATC-Codes ............................................................................
    [Show full text]
  • Pharmacological Interventions for Acute Pancreatitis (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Cochrane Database of Systematic Reviews Pharmacological interventions for acute pancreatitis (Review) Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, Gurusamy KS Moggia E, Koti R, Belgaumkar AP, Fazio F, Pereira SP, Davidson BR, Gurusamy KS. Pharmacological interventions for acute pancreatitis. Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD011384. DOI: 10.1002/14651858.CD011384.pub2. www.cochranelibrary.com Pharmacological interventions for acute pancreatitis (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 8 OBJECTIVES ..................................... 9 METHODS ...................................... 9 Figure1. ..................................... 12 RESULTS....................................... 15 Figure2. ..................................... 16 Figure3. ..................................... 17 Figure4. ..................................... 22 Figure5. ..................................... 23 Figure6. ..................................... 24 Figure7. ..................................... 25 Figure8. ..................................... 26 ADDITIONALSUMMARYOFFINDINGS . 26 DISCUSSION ....................................
    [Show full text]